Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renin-Angiotensin System Quantification in patients treated with Aliskiren or Candesartan (RASQAL)
2012-000250-55Phase 4Completed
- Sponsor
- Medical University of Vienna
- Start
- Jun 2012
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of aliskiren and candesartan in chronic kidney disease (CKD) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Quantitative RAS peptide changes. Started Jun 2012; status: completed.
02
Drugs
aliskirencandesartan
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2012-000250-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000250-55.